Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine - Wikidata - awgldk - TriplyDB

Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine

Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine

http://www.wikidata.org/entity/Q35284997

about

Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions.Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile

P2860

Q33662388-0384F6E9-20DF-4B27-BC19-83516B1FFAEA Q34423181-702607CB-3683-4363-83A7-244ABE9E90D7 Q35669185-6DBFD6CF-DAAC-467B-88F0-A51A6A428666 Q36296864-C141B4AD-B995-4684-868A-5408C4B05C5E Q36638633-0C637914-F1A8-4B59-9034-D00D2E1E1134 Q36849604-BA63DFD4-3129-45A5-ACFC-F2B511E5DA74 Q37264264-E0D6AF75-39FF-499C-AB64-C513AE2D0A5B Q37340687-CBD12165-2436-4D6C-89B6-A0ACF27AC18F Q38862468-1B19D1D8-7777-4BAA-8E8B-051699C162AC Q39194989-297587FF-FA93-4F09-ABDE-F847D5570E5B Q57073139-D3585D9A-ADF4-4433-85E7-B4A77086A4B6

P2860

Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine

http://www.wikidata.org/entity/Q35284997

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Structural determinants of opi ...... n derivatives of buprenorphine

@ast

Structural determinants of opi ...... n derivatives of buprenorphine

@en

type

label

Structural determinants of opi ...... n derivatives of buprenorphine

@ast

Structural determinants of opi ...... n derivatives of buprenorphine

@en

prefLabel

Structural determinants of opi ...... n derivatives of buprenorphine

@ast

Structural determinants of opi ...... n derivatives of buprenorphine

@en

P1433

Q35284997-FA1FE172-2D32-42E7-A70B-330269986636

P1476

Q35284997-DD2857DC-ECE6-4576-8F37-96EACDC7C15A

P2093

Q35284997-08790AF2-32F7-46CF-8034-79F5DEEB2D96

Q35284997-28661292-F679-42AF-8E42-1A3809995106

Q35284997-AEC67729-93DA-49BD-967D-5E8DFC4C6CCD

Q35284997-D2EC76E9-AE6C-412B-8B19-975A0C8CD165

P2860

Q35284997-13C19561-EA37-467B-B3F2-116EFE4183DC

Q35284997-1BDB3857-9C09-4AAE-AFD9-3FBDED1ADF72

Q35284997-2DC02F95-C062-4911-B8B2-EFF9BA5C0624

Q35284997-30C294B0-9367-4955-B4D3-BCB47CB23643

Q35284997-338A254F-27C2-489F-864B-65FF5310F4D4

Q35284997-4336C393-7D1E-430D-B4BB-4D909F764CAB

Q35284997-54EF352A-6B53-4C25-BCF6-91B12393073E

Q35284997-5629D417-C7F3-4EB6-B6D1-84DBD86DEDCC

Q35284997-739019D2-74E9-4220-9E8B-47CC1C4984D0

Q35284997-7420BCE9-95E6-4E2E-BD8B-48C85A61E70D

P304

Q35284997-25DCCD6C-9D2D-4A7D-B256-7157B6C15A4E

P31

Q35284997-465616A5-C2BE-4D43-BD0A-F28FEFFC0D4E

P356

Q35284997-DA22151B-0309-4528-936C-DB5E10E47304

P407

Q35284997-A515B545-0BD9-4776-B046-FF929AAC647A

P433

Q35284997-9800DED3-5280-4437-B715-B7D6D0811043

P478

Q35284997-94CAFFCC-FEA6-471D-B73D-0239647FB9FD

P50

Q35284997-C823E5E4-D4F0-4797-A79E-D0E048E53648

P577

Q35284997-C2790DE0-BD53-47B9-8518-91641C25C3CF

P5875

Q35284997-705FE8FB-EDAF-45B2-812A-9AA892D2D2B2

P698

Q35284997-660E8C5F-B217-4630-9CD9-18C0C79D29F1

P932

Q35284997-B1EAD922-01AE-4C74-9E3B-692259366FA3

P356

P1433

Journal of Medicinal Chemistry

P1476

Structural determinants of opi ...... n derivatives of buprenorphine

@en

P2093

Lawrence Toll

http://www.w3.org/2001/XMLSchema#string

Stephen M Husbands

http://www.w3.org/2001/XMLSchema#string

Taline V Khroyan

http://www.w3.org/2001/XMLSchema#string

Willma E Polgar

http://www.w3.org/2001/XMLSchema#string

P2860

Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay

Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP

Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111)

Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist

2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide: an opioid receptor affinity label that produces selective and long-lasting kappa antagonism in mice

A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat.

Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors

In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.

Animal models of nociception.

Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse.

P304

6531-6537

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM2003238

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

Gerta Cami-Kobeci

P577

2011-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51595128

http://www.w3.org/2001/XMLSchema#string

P698

21866885

http://www.w3.org/2001/XMLSchema#string

P932

3188691

http://www.w3.org/2001/XMLSchema#string